Form 4: HilleVax Director Aditya Kohli Sells Shares Under 10b5-1 Trading Plan

Director Aditya Kohli of HilleVax, Inc. executed sales of common stock between May 1 and May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Aditya Kohli, a director of HilleVax, Inc., reported the sale of common stock in a Form 4 filing with the SEC.
• The transactions occurred between May 1, 2024, and May 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on October 12, 2023.
• A total of 7,898 shares were sold across the three days.
• The weighted average sale prices ranged from $14.0135 to $14.1542 per share.
• Following the reported transactions, Kohli beneficially owns 782,878 shares of HilleVax, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Comparison to Industry Standards

• Comparing these transactions to similar insider sales at comparable biotech companies requires analyzing the percentage of holdings sold and the context of the company's performance.
• For example, if a CEO of a similar-sized biotech company like IGM Biosciences (IGMS) or Arcus Biosciences (RCUS) sold a similar percentage of their holdings, it would be important to consider the timing relative to clinical trial results or regulatory milestones.
• Without this context, it's difficult to assess whether these sales are unusual or concerning.

Stakeholder Impact

• The sale of shares by a director could potentially create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates